Edwards Lifesciences Stock News

Nordea Investment Management AB grew its stake in Edwards Lifesciences Co. (NYSE:EW) by 95.2% during the third quarter, Holdings Channel reports. The firm owned 414,056 shares of the medical research company’s stock after purchasing an additional 201,912 shares during the period. Nordea Investment Management AB’s holdings in Edwards Lifesciences were worth $47,518,000 as of its […]

Edwards Lifesciences Corp (EW) shares closed today at 0.4% below its 52 week high of $129.12, giving the company a market cap of $80B. The stock is currently up 40.9% year-to-date, up 45.6% over the past 12 months, and up 314.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 27.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 492.6% The company's stock price performance over the past 12 months beats the peer average by 331.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -48.5% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Edwards Lifesciences Corp (EW) shares closed today at 0.1% below its 52 week high of $128.02, giving the company a market cap of $79B. The stock is currently up 40.1% year-to-date, up 45.3% over the past 12 months, and up 317.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.2%, and the S&P 500 rose 0.3%. Trading Activity Trading volume this week was 27.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 589.6% The company's stock price performance over the past 12 months beats the peer average by 388.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -47.9% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The "Halftime Report" traders give their top picks to watch for the second half.

The global Clot Management Devices market was valued at 1242.65 Million USD in 2020 and will grow with a CAGR of 3.89% from 2021 to 2027. The key variables driving the development of clot management devices market are rising commonness

Edwards Lifesciences Corp (EW) shares closed 0.7% higher than its previous 52 week high, giving the company a market cap of $74B. The stock is currently up 31.6% year-to-date, up 38.3% over the past 12 months, and up 296.3% over the past five years. This week, the Dow Jones Industrial Average fell 2.0%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 7.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 1791.3% The company's stock price performance over the past 12 months beats the peer average by 641.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -49.0% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

WD Rutherford LLC trimmed its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 0.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,175 shares of the medical research company’s stock after selling 130 shares during the quarter. Edwards Lifesciences accounts […]

Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.

What to Expect From the Markets In 2022

Pantheon Investment Group LLC lowered its holdings in Edwards Lifesciences Co. (NYSE:EW) by 4.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 18,896 shares of the medical research companys stock after selling 917 shares during the quarter. Edwards Lifesciences comprises 1.8% of Pantheon Investment []

Trust Asset Management LLC cut its stake in Edwards Lifesciences Co. (NYSE:EW) by 3.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,051 shares of the medical research companys stock after selling 241 shares during the quarter. Trust Asset Management LLCs []

Edwards Lifesciences Co. (NYSE:EW) hit a new 52-week high during trading on Friday . The company traded as high as $123.56 and last traded at $122.09, with a volume of 58569 shares trading hands. The stock had previously closed at $119.57. Several equities research analysts have issued reports on EW shares. SVB Leerink raised their []

Edwards Lifesciences (NYSE:EW) was upgraded by equities research analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating in a research report issued to clients and investors on Friday, PriceTargets.com reports. The firm currently has a $140.00 target price on the medical research companys stock, up from their previous target price []

RDA Financial Network boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 0.6% during the third quarter, HoldingsChannel.com reports. The fund owned 18,484 shares of the medical research companys stock after acquiring an additional 117 shares during the period. RDA Financial Networks holdings in Edwards Lifesciences were worth $2,093,000 as of its most recent filing []

Stephens Inc. AR lifted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,896 shares of the medical research companys stock after acquiring an additional 405 shares during the period. Stephens Inc. []